Please ensure Javascript is enabled for purposes of website accessibility

Why NVR, Insperity, and Omeros Slumped Today

By Dan Caplinger - Nov 4, 2019 at 4:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Find out why these stocks missed out on the market rally.

Wall Street kept celebrating on Monday, delivering fresh record highs for the major benchmarks in the process. As long as trade discussions between China and the U.S. appear to be going relatively smoothly and have a chance at eventual success, investors seem willing to look past those issues and focus on more general economic strength. Yet some companies had to deal with less-than-perfect news that sent their share prices lower. NVR (NVR -1.44%), Insperity (NSP -1.04%), and Omeros (OMER -3.12%) were among the worst performers. Here's why they did so poorly.

NVR sinks with homebuilders

Shares of NVR fell 7%, leading just about the entire homebuilding industry lower. Investors in homebuilder stocks have faced a tug of war in recent days, as some analysts have argued that after a strong run higher for NVR and its peers, a pullback in the housing market is warranted because of future uncertainty. Yet others believe that reductions in short-term interest rates will help keep the longer-term rates that determine mortgage costs in check as well, and that could help extend the cyclical strength in homebuilders for a while longer. Long-term rates did move higher Monday, but it'd take a much larger uptick to have a marked impact on mortgage activity and thereby hurt NVR.

Kitchen with white cabinets and wood floor along with island in middle.

Image source: NVR.

Insperity loses its inspiration

Insperity saw its stock plunge 34% after the human resources and business specialist released poor third-quarter financial results. Revenue was higher by 13% compared to the year-earlier period, but adjusted earnings per share fell 22%. CEO Paul Sarvadi pointed to "disappointing" activity levels in large medical claims, but he tried to emphasize that Insperity's long-term strategy remained intact. Nevertheless, investors kept their eyes focused squarely on short-term impacts, and Insperity's reduction in full-year earnings guidance came as a huge shock to those who'd had high hopes for the high-growth company.

Omeros takes a Medicare hit

Finally, shares of Omeros sank 16%. The maker of the Omidria treatment for cataracts fell following news that a new rule from the Centers for Medicare & Medicaid Services included a finding that the treatment didn't significantly reduce fentanyl usage during surgery. Omeros CEO Gregory Demopulos tried to highlight the "perverse incentive" that an adverse decision against Omidria might have in encouraging greater opioid use. Even so, shareholders seem worried that an ongoing look from Medicare to evaluate the benefits of Omidria might not result in the positive outcomes that Omeros and its chief executive expect.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Insperity, Inc. Stock Quote
Insperity, Inc.
NSP
$96.94 (-1.04%) $-1.02
NVR, Inc. Stock Quote
NVR, Inc.
NVR
$4,231.79 (-1.44%) $-61.78
Omeros Corporation Stock Quote
Omeros Corporation
OMER
$3.10 (-3.12%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.